Inventurus Knowl

Inventurus Knowledge Solutions reported robust financial results for Q2 FY26, with revenue growing 22% year-on-year and 5.5% quarter-on-quarter to INR 781 crores. This growth translated into significant profitability, with EBITDA expanding 43% YoY and 14% QoQ to INR 272 crores, achieving an EBITDA margin of approximately 35%. Net profit also saw substantial growth, increasing 60% YoY and 19% QoQ to INR 181 crores, resulting in an EPS of INR 10.8 and a healthy ROE of 32%.

The company emphasized its transition to an AI-native and agentic platform, integrating autonomous clinical documentation with financial workflows. This platform is designed to solve cost, quality, and access challenges in the $5 trillion U.S. healthcare system. Management highlighted continued progress in leveraging AI for denial prevention, patient financial clearance, optimized scheduling, and physician productivity, transforming unstructured data into structured, meaningful insights.

The successful integration of the AQuity acquisition, now almost two years in, has been a key driver of margin expansion. The company transformed AQuity's delivery model through technology and global human execution, achieving its target EBITDA margins in the mid-30s several quarters ahead of schedule. This efficiency gain, coupled with the AI-driven elimination of human intervention, significantly contributed to the improved bottom line performance.

IKS's strategy focuses on deep penetration within a cohort of approximately 50 enterprise-scale customers, each with a potential of $50 million ACV over the next five years, which could generate $0.5 billion to $750 million in additional growth. The company secured new client wins and expansions, including AdventHealth, Revere Health, The Jackson Clinic, and a leading cardiology group, demonstrating strong platform adoption. While top clients show robust growth, management noted that growth in non-top 10 clients remains 'choppy' due to ongoing client rationalization post-AQuity acquisition, aiming for long-term relationships with the top 500 clients.

The company maintains a capital-light business model, generating strong cash flows, with operating cash flow at INR 291 crores and free cash flow at INR 225 crores, yielding a 124% FCF. Net debt reduced to INR 412 crores this quarter, and management aims to be net debt-free by FY27, supported by strong cash generation and a refinanced term loan at a more attractive interest rate. Capital allocation priorities include strategic tuck-in technology acquisitions and aligning with customer outcomes through long-term platform deals.

The U.S. healthcare market, particularly the physician segment, represents a $260 billion TAM growing at 8%, with the outsourced TAM growing at 12%. IKS aims to gain market share by growing faster than 12%. Management addressed competitive concerns regarding large players like Optum, clarifying that IKS primarily targets the physician market, while Optum's core RCM strength is hospital-focused. Strategic integrations, such as with Epic Electronic Health Record software, are deemed critical for IKS's competitive advantage in serving large health systems.